<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524601</url>
  </required_header>
  <id_info>
    <org_study_id>RITA-11</org_study_id>
    <nct_id>NCT01524601</nct_id>
  </id_info>
  <brief_title>The Rosuvastatin In TrAnsplant Recipients Study</brief_title>
  <acronym>RITA</acronym>
  <official_title>The RITA-study -- An Open Study to Evaluate the Blood Lipid Lowering Effect of Rosuvastatin Versus Fluvastatin and the Bilateral Interaction Between Everolimus and Rosuvastatin in Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo School of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo School of Pharmacy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal transplant recipients need life long immunosuppression and one of the new drugs is
      everolimus. Everolimus is a potent immunosuppressive drug and one of the main side-effects
      are increased blood cholesterol levels. Many renal transplant recipients are treated with a
      cholesterol lowering agent, mainly fluvastatin. Rosuvastatin is a new cholesterol lowering
      drug on the market with a potential higher cholesterol lowering potency. In the present study
      the investigators will examine the hypothesis that rosuvastatin reduce cholesterol levels
      more than fluvastatin in renal transplant patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare the treatment efficacy (blood lipid lowering effect) of rosuvastatin versus fluvastatin</measure>
    <time_frame>4 weeks</time_frame>
    <description>Compare the blood lipid levels before and after switch from fluvastatin to rosuvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC) of rosuvastatin in renal transplant recipients treated with everolimus. Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post dose.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Compare 24-h pharmacokinetics of renal transplant recipients with historic controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Area Under Curve (AUC) of everolimus during rosuvastatin versus fluvastatin therapy, including intracellular everolimus concentrations within T-lymphocytes. Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Investigate P-gp activity in whole blood in everolimus treated patients</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Study inter individual variation in rosuvastatin and everolimus pharmacokinetics in renal transplant recipients due to polymorphism in the genes encoding P-gp, OATP1B1 and CYP3A5</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Compare effect of rosuvastatin versus fluvastatin therapy on the renal function (eGFR)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin treatment for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20 mg rosuvastatin for 4 weeks</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant recipients with stable renal function (plasma creatinine &lt; 200
             µmol/L)

          -  Renal transplant recipients on an everolimus and fluvastatin based therapy for minimum
             3 months prior to inclusion

          -  &gt; 18 years of age

          -  Male patient or female patient without childbearing potential (surgically sterilized
             or postmenopausal) or if female of childbearing potential; is not lactating, has a
             negative pregnancy test at screening and is willing to utilize an effective method of
             contraception throughout the study period and for 90 days following discontinuation of
             the study drugs

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients experiencing an acute rejection episode within 2 weeks before or after
             inclusion, whether proven by biopsy or not

          -  Patients with a known hypersensitivity to rosuvastatin

          -  Change in enzyme inducing or inhibiting drugs within the last 2 weeks prior to and
             throughout the study [e.g. barbiturates, rifampicin, ketoconazole, erythromycin,
             cimetidine and similar drugs]

          -  Pregnant or nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Åsberg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <last_update_submitted>October 11, 2012</last_update_submitted>
  <last_update_submitted_qc>October 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <keyword>Everolimus</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>fluvastatin</keyword>
  <keyword>Lipid lowering</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

